Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23

Internal Medicine

Volumn 47, Issue 10, 2008, Pages 957-961

  Nasu, Tetsushi ^a   Kurisu, Seigo ^a   Matsuno, Shohei ^a   Tatsumi, Kunihiro ^a   Kakimoto, Tetsuhiro ^a   Kobayashi, Masato ^a   Nakano, Yoshio ^a   Wakasaki, Hisao ^a   Furuta, Hiroto ^a   Nishi, Masahiro ^a   Sasaki, Hideyuki ^a   Suzuki, Hisanori ^b   Ito, Nobuaki ^b   Fukumoto, Seiji ^b   Nanjo, Kishio ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

FGF23; MRI; Tumor induced osteomalacia; Venous sampling

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; BONE RADIOGRAPHY; BONE SCINTISCANNING; CASE REPORT; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FIBROMA; FRACTURE; HUMAN; ILIAC VEIN; LEG PAIN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; PROTEIN BLOOD LEVEL; VENOUS BLOOD; BLOOD; BONE TUMOR; DIFFUSION WEIGHTED IMAGING; FEMORAL VEIN; FEMUR; HYPOPHOSPHATEMIA; OSTEOMALACIA; PARANEOPLASTIC SYNDROME; PATHOLOGY;

ADULT; BONE NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMORAL VEIN; FEMUR; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA; MALE; OSTEOMALACIA; PARANEOPLASTIC SYNDROMES;

EID: 45849113239     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0745     Document Type: Article

References (16)

1. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28: 1-30, 2004.
2. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505, 2001.
3. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet 2: 309-310, 1975.
4. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002.
5. Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89: 3979-3982, 2004.
6. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38: 1248-1250, 2006.
7. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315, 2006.
8. Hesse E, Moessinger E, Rosenthal H, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 22: 158-162, 2007.
9. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359: 761-763, 2002.
10. Seufert J, Ebert K, Muller J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345: 1883-1888, 2001.
11. Yoshioka K, Nagata R, Ueda M, et al. Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy. Intern Med 45: 1157-1160, 2006.
12. Fukumoto S, Takeuchi Y, Nagano A, Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 25: 375-377, 1999.
13. Imanishi Y, Nakatsuka K, Nakayama T, et al. False-positive magnetic resonance imaging skeletal survey in a patient with sporadic hypophosphatemic osteomalacia. J Bone Miner Metab 21: 57-59, 2003.
14. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314: 409-414, 2004.
15. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143: 3179-3182, 2002.
16. Ito N, Fukumoto S, Takeuchi Y, et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 23: 435-440, 2005.